Sponsor:
CG Oncology, Inc.
Code:
NCT04452591
Conditions
Non Muscle Invasive Bladder Cancer
High-grade Ta/ T1 Papillary Disease Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cretostimogene Grenadenorepvec
n-dodecyl-B-D-maltoside
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by CG Oncology, Inc. on 2025-01-06.